Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Progress in Parkinson's disease].

Yoshikuni Mizuno1

  • 1Department of Neurology, Juntendo University School of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|October 7, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

More than 20 years of the discovery of Park2.

Neuroscience research·2020
Same author

Long-Term Selegiline Monotherapy for the Treatment of Early Parkinson Disease.

Clinical neuropharmacology·2019
Same author

<sup>123</sup>I-MIBG myocardial scintigraphy for the diagnosis of DLB: a multicentre 3-year follow-up study.

Journal of neurology, neurosurgery, and psychiatry·2018
Same author

A Randomized Double-Blind Placebo-Controlled Phase III Trial of Selegiline Monotherapy for Early Parkinson Disease.

Clinical neuropharmacology·2017
Same author

Twenty years since the discovery of the parkin gene.

Journal of neural transmission (Vienna, Austria : 1996)·2017
Same author

Long-term treatment of Parkinson's disease with levodopa and other adjunctive drugs.

Journal of neural transmission (Vienna, Austria : 1996)·2017
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles

Recent advancements in Parkinson's disease include new treatment guidelines and diagnostic tools like MIBG SPECT. Familial Parkinson's research reveals alpha-synuclein and parkin gene mutations, highlighting oxidative damage as a common pathogenic mechanism.

Area of Science:

  • Neurology
  • Neuroscience
  • Genetics

Background:

  • Parkinson's disease (PD) research has seen significant progress, with new treatment guidelines and diagnostic approaches.
  • Familial PD studies have illuminated the pathogenesis of sporadic forms.
  • Alpha-synuclein and parkin gene mutations are implicated in PD development.

Purpose of the Study:

  • To summarize recent advancements in Parkinson's disease treatment and pathogenesis.
  • To highlight the diagnostic utility of MIBG SPECT for cardiac sympathetic endings in PD.
  • To explore the common pathogenic mechanisms in different forms of Parkinson's disease.

Main Methods:

  • Review of EBM-based systematic drug reviews and treatment algorithms for PD.
  • Analysis of MIBG SPECT findings in Lewy body-positive PD patients.

Related Experiment Videos

  • Examination of genetic mutations (alpha-synuclein, parkin) in familial PD.
  • Investigation into the role of oxidative damage in nigral neurodegeneration.

    • Main Results:

    • Japanese Neurological Society published new PD treatment guidelines.
    • MIBG SPECT shows decreased uptake in cardiac sympathetic endings in most PD patients.
    • Alpha-synuclein gene mutations (including triplication) and parkin gene mutations (PARK2) are linked to PD.
    • Oxidative damage is a key factor in nigral neurodegeneration across different PD forms.

    Conclusions:

    • A common pathogenic mechanism, involving oxidative damage, is present in various forms of Parkinson's disease.
    • Future research for neuroprotective drugs should focus on this shared mechanism.
    • MIBG SPECT is a valuable diagnostic tool for early-stage PD.